• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of pnasPNASInfo for AuthorsSubscriptionsAboutThis Article
Proc Natl Acad Sci U S A. Jun 25, 2002; 99(13): 8880–8885.
Published online Jun 18, 2002. doi:  10.1073/pnas.122249299
PMCID: PMC124392
Medical Sciences

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

Abstract

The ErbB2 (Her2) proto-oncogene encodes a receptor tyrosine kinase, which is frequently amplified and overexpressed in human tumors. ErbB2 provides the target for a novel and effective antibody-based therapy (Trastuzumab/Herceptin) used for the treatment of mammary carcinomas. However, cardiomyopathies develop in a proportion of patients treated with Trastuzumab, and the incidence of such complications is increased by combination with standard chemotherapy. Gene ablation studies have previously demonstrated that the ErbB2 receptor, together with its coreceptor ErbB4 and the ligand Neuregulin-1, are essential for normal development of the heart ventricle. We use here Cre-loxP technology to mutate ErbB2 specifically in ventricular cardiomyocytes. Conditional mutant mice develop a severe dilated cardiomyopathy, with signs of cardiac dysfunction generally appearing by the second postnatal month. We infer that signaling from the ErbB2 receptor, which is enriched in T-tubules in cardiomyocytes, is crucial for adult heart function. Conditional ErbB2 mutant mice provide a model of dilated cardiomyopathy. In particular, they will allow a rigorous assessment of the role of ErbB2 in the heart and provide insight into the molecular mechanisms that underlie the adverse effects of anti-ErbB2 antibodies.

Dilated cardiomyopathies are an important cause of heart failure (1). Affected patients present with ventricular dilatation, thinned ventricle walls, and reductions in pumping efficiency, leading typically to congestive heart failure and premature death. Diverse mechanisms can cause dilated cardiomyopathies leading to heart failure, like ischemic injury or infection. Epidemiological studies suggest that 25–30% of dilated cardiomyopathies are inherited (1). Among the genes that, when mutated, cause dilated cardiomyopathies in humans and mice are those encoding intrasarcomeric and extrasarcomeric cytoskeletal proteins (1, 2). Mutations in these known genes account for only a minor proportion of the heritable cardiomyopathies in humans. In the mouse, mutations in the bradykinin-B2 and serotonin-2B receptor genes also cause dilated cardiomyopathies (3, 4), whereas components of calcium homeostasis or the β-adrenergic system can, when altered genetically, prevent their development (5). Thus, alterations in the fine tuning of contractility or the adaptive responses to cardiac load can contribute to the development of this disease.

The ErbB2 receptor tyrosine kinase was originally identified due to its potent oncogenic activity (6, 7). Biochemical studies and gene ablation in the mouse revealed that ErbB2 functions as a coreceptor in Neuregulin signaling (6, 8, 9). ErbB2 heteromerizes with ErbB3 and ErbB4, the high-affinity receptors for Neuregulin, and is essential for transmission of the Neuregulin signal (6). Moreover, ErbB2 participates in signaling of the epidermal growth factor receptor, gp130/cytokine receptors and G-coupled receptors in cultured cells (10). ErbB2/4 receptors and Neuregulin-1 are essential for heart development: mutations in Neuregulin-1, ErbB2, or ErbB4 in mice result in impaired ventricular trabeculation, causing midgestation lethality. During development, Neuregulin-1 signals are provided by the endocardium and received by the ErbB2/ErbB4 receptors in the myocardium (8, 11). In addition, the ErbB2/ErbB4 receptors as well as Neuregulins remain expressed in the adult heart.

Overexpression or amplification of ErbB2 is frequently associated with carcinomas, prompting its selection as a target for novel therapeutic agents (6, 7). The humanized antibody, Trastuzumab (also known as Herceptin), is directed against the extracellular domain of human ErbB2. Trastuzumab recognizes ErbB2 on the cell surface, dimerizes the receptor, and rapidly promotes its internalization and down-regulation (12). Trastuzumab elicits an antiproliferative effect in cells overexpressing human ErbB2 (12). In vivo, recruitment of the immune system might enhance its antitumorigenic properties (12). Combination treatment of Trastuzumab and chemotherapeutics is an effective clinical therapy for malignant breast tumors that overexpress ErbB2. It lengthens time to disease progression, life expectancy, and reduces the risk of death (13). A fraction of patients that undergo such a combination treatment, however, develops cardiac dysfunction (13). This observation might indicate that the target, ErbB2, functions in homeostasis of the adult heart. The effects of Trastuzumab on heart function cannot be analyzed in animal models as the antibody recognizes specifically the human ErbB2 protein only.

To address the function of ErbB2 in the postnatal heart, we mutated ErbB2 specifically in cardiomyocytes of mice. For this purpose, mice that express Cre recombinase under the control of the MLC2v (myosin light chain 2v) locus were used (14, 15). Conditional ErbB2 mutants were born at the expected Mendelian frequency, and most reached adulthood but developed severe dilated cardiomyopathy with a typical onset in the second month of age. Our analysis indicates ErbB2 is not required for survival of cardiomyocytes and demonstrates a function of ErbB2 in normal heart physiology. Impairing ErbB2 activity in the heart can thus directly cause cardiomyopathy and heart failure.

Materials and Methods

Mouse Strains.

The ErbB2flox, ErbB2 , and MLC2vcre alleles have been described (14, 16, 17). Genotyping of the animals was performed by PCR and occasionally verified by Southern blot analysis. Conditional mutant mice with the genotype MLC2vcre/+; ErbB2flox/− displayed reduced survival. Sixteen percent died within the first two postnatal weeks (9 of a total of 58); the remainder reached adulthood. A cohort of 22 conditional mutant animals was set aside to assess the frequency of sudden death, and of those, 27% died before reaching the age of 6 mo. Moreover, a proportion of conditional mutant mice (20%) died during echochardiographic or ECG examinations (3 of 15). Three genotypes were used as control animals: MLC2vcre/+; ErbB2flox/+ (Southern hybridization, echocardiography), ErbB2flox/− (echocardiography and microarray analysis), and ErbB2flox/+ (echocardiography).

Immunostaining and Histology.

Tissues were isolated from mice perfused with 4% paraformaldehyde, cryoprotected with 20% sucrose, and frozen in Oct compound (Sakura, Torrance, CA). Cryosections (12 μm) were stained with the following antibodies: rabbit polyclonal against ErbB2 (Santa Cruz Biotechnology; 1:100), ErbB4 (Santa Cruz Biotechnology; 1:100), anti-ErbB4 serum no. 0616 (a gift from Cary Lai, Scripps Research Institute, San Diego, CA; 1:1,500), mouse monoclonal anti-vinculin (Sigma; 1:300), and Cy2- or Cy3- conjugated secondary antibodies (Dianova, Hamburg, Germany; 1:200). T-tubule staining using anti-ErbB4 antibodies was observed with two additional rabbit polyclonal sera raised against ErbB4 (sera nos. 0615 and 0618; gifts from Cary Lai), i.e., all anti-ErbB4 sera tested. T-tubule staining with anti-ErbB2 was reproducibly observed with one antibody batch (Santa Cruz Biotechnology, lot no. A087), whereas results obtained with a second batch were variable (Santa Cruz Biotechnology, lot no. H145). Histological, BrdUrd, and terminal deoxynucleotidyltransferase-mediated dUTP end labeling (TUNEL) and electron microscopical analyses were performed as described (16).

Determination of Cre-Mediated Recombination Specificity and Efficiency.

The specificity of recombination was also verified by using the reporter Z/AP, which expresses alkaline phosphatase on Cre-mediated recombination (18). Cryosections (6 μm), from 1- and 6-week-old mice double heterozygous for the alleles MLC2vcre and Z/AP were fixed and stained as described (18). We observed alkaline phosphatase staining in ventricular cardiomyocytes and in nodal tissue of the atria. Cardiac endothelia were not stained. Preparations enriched in cardiomyocytes were prepared from adult hearts as described (19).

Echocardiography and Aortic Banding.

A two-dimensional short-axis view of the left ventricle was obtained with a 12-MHz transducer (Acuson Sequoia, Erlangen, Germany) in anesthetized mice. M-mode tracings were recorded and used to determine the diameter of the left ventricle at the end of the diastole (LVEDD) and systole (LVESD). Fractional shortening, a measure of the pumping function of the heart, corresponds to the value of (LVEDD-LVESD)/LVEDD. Statistical significance was assessed by using the Mann–Whitney test for nonparametric distributions. Abdominal aortic stenosis (banding) was performed as described (20).

Gene Expression Profiling Using Affymetrix Microarrays.

P12 mouse ventricular tissue was homogenized in Trizol reagent (GIBCO); isolated total RNA was purified on RNeasy microcolumns (Qiagen, Chatsworth, CA). Biotinylated cRNA was prepared from 20 μg of total RNA, hybridized to Affymetrix genechip Murine 11-K arrays, stained with streptavidin–phycoerythrin (Molecular Probes) and scanned on a laser confocal scanner (Hewlett–Packard) according to the manufacturers' instructions. Fluorescence intensity values were analyzed by using MICROARRAY SUITE 5.0 (Affymetrix) and were scaled by using a target intensity value of 1,000. Changes in gene expression between conditional mutants and controls were calculated by dividing the mean signal intensities. Statistical significance was assessed by using Student's t test.

Results

Distribution of the ErbB2 Receptor in the Adult Murine Heart.

ErbB2 and ErbB4 mRNA and protein are produced in the adult and embryonic heart (11, 21). We found that ErbB2 and ErbB4 receptors are distributed nonhomogeneously in adult cardiomyocyte membranes. Immunoreactivity of ErbB2 and ErbB4 is associated with periodic banded structures, the T-tubular network (Fig. (Fig.1),1), which also stain with anti-vinculin antibodies (Fig. (Fig.1)1) (22). T-tubules are formed by invaginations of the sarcolemma membrane, which remain connected to the extracellular space and in which essential components of the excitation–contraction coupling machinery are located. With shortened fixation times, ErbB2/ErbB4 staining is also observed in intercalated discs (not shown). A similar distribution of ErbB2/4 in the T-tubular system is observed also in skeletal muscle (not shown).

Figure 1
ErbB2 and ErbB4 are enriched in the T-tubules of adult mouse ventricular cardiomyocytes. Cryosections were stained with antibodies against ErbB2 (A) or ErbB4 (B) and colabeled with anti-vinculin antibodies (C and D). ErbB2 (A and C, red) and ErbB4 (B ...

Cre-Induced Mutation of ErbB2 in Cardiomyocytes.

To introduce cardiomyocyte-specific mutations into ErbB2, we used the MLC2vcre allele. ErbB2flox/ErbB2flox mice were crossed with mice heterozygous for a null mutation of ErbB2 that also carry the MLC2vcre allele (MLC2vcre/+; ErbB2+/−), to obtain conditional mutant mice (MLC2vcre/+; ErbB2flox/− (Fig. (Fig.22A; see also Materials and Methods). Recombination efficiencies were determined by Southern blot analysis of genomic DNA isolated from cardiomyocyte preparations of the heart ventricles. MLC2vcre specifically introduced recombination of the ErbB2flox allele in 50–60% of the cardiomyocytes, resulting in a mosaicism of the heart muscle (Fig. (Fig.22B). Recombination in other tissues was not detected. Similar amounts of the recombined ErbB2 allele were present in cardiomyocyte preparations from 5- to 6-mo-old conditional mutant (MLC2vcre/+; ErbB2flox/− and control (MLC2vcre/+; ErbB2+/−) mice, demonstrating that homozygous mutant cells were not preferentially lost. ErbB2 and ErbB4 protein were detectable in ventricular tissue of adult conditional mutants and controls, which contains cardiomyocytes and other cell types (Fig. (Fig.22B).

Figure 2
Cre-mediated mutation of ErbB2 in ventricular cardiomyocytes. (A) Schematic representation of the ErbB2 locus, indicating restriction enzyme sites (black arrowheads: B, BamH1; RV, EcoRV), loxP sequences (red arrowheads), sizes and positions of fragments ...

Conditional ErbB2 Mutants Develop Severe Heart Dysfunction After Birth.

In offspring from matings between ErbB2flox/flox mice and MLC2vcre/+; ErbB2± mice, a normal Mendelian ratio of conditional mutants was found, and thus embryonic lethality was not observed. Ventricular trabeculae of conditional ErbB2 mutants were well developed at embryonic day (E)10.5 and E15.5, and no morphological or histological abnormalities were observed at these stages (eight conditional mutant animals analyzed; Fig. Fig.22 CE and data not shown). Heart diameter and function in individual mice that reached adulthood were followed by ultrasound echocardiography over time (Fig. (Fig.3).3). At 1 mo of age, the average left ventricular end-diastolic diameter was similar in control and conditional mutant mice, but dilatation and a loss of contractility became marked subsequently. At the age of 3 mo, the ventricular diameter reached an average value of 4.3 mm in conditional mutants compared with 3.3 mm in control mice (Fig. (Fig.33C and data not shown). Fractional shortening, a measure of heart-pumping function, became markedly impaired in the aging conditional mutants (Fig. (Fig.33D). Moreover, ECG examination demonstrated a significantly lengthened QTc interval (+23%, n = 23 vs. 15, P = 0.014) caused by a slowed ventricular repolarization in the conditional mutants. Thus, a progressive malfunction of the heart was observed in aging conditional ErbB2 mutant mice. Moreover, a proportion of the conditional mutant mice died prematurely. Sudden death of conditional mutants was also observed during echocardiographic and ECG examinations, which were performed under anesthesia.

Figure 3
Conditional ErbB2 mutants develop marked deficits in heart function. Representative examples of ultrasound images of the left ventricle from control (A) and conditional ErbB2 mutant (B) 3-mo-old mice used to determine left ventricular end-diastolic (LVEDD) ...

To analyze the response of conditional mutant hearts to increased stress, abdominal aortic banding was performed. This reduces the diameter of the aorta and results in stress on the heart, which has to pump against an increased resistance. In control mice, the increased working load was compensated for by increased fractional shortening 1 wk after aortic banding (Fig. (Fig.33 C and D). In contrast, the conditional mutant hearts did not compensate after aortic banding, but displayed a further decrease in fractional shortening (Fig. (Fig.33D).

Histology of adult conditional mutant hearts revealed enlarged ventricular chambers with thinned walls, and myofiber hypertrophy (Fig. (Fig.44 AD). In 3-mo-old conditional mutant hearts, cardiomyocytes, despite being hypertrophic, had normal myofibrillar architecture and intercellular junctions when examined by electron microscopy (Fig. (Fig.44 E and F and data not shown). However, enlarged cardiomyocyte nuclei with abnormal morphology were frequently observed. Heart-to-body-weight ratios of adult conditional mutants were increased relative to control by 26% (n = 8 per group, P = 0.001), a further indication of hypertrophy. Terminal deoxynucleotidyltransferase-mediated dUTP end labeling (TUNEL) staining did not reveal significant changes in apoptosis rates (1.4 ± 0.2 TUNEL-positive nuclei per field in adult conditional mutant and 1.1 ± 0.2 in control hearts). Apoptosis rates were also similar in adult control and conditional mutant mice 1 wk after aortic banding (1.7 ± 0.3 positive nuclei in conditional mutant and 2.2 ± 0.4 in control hearts). Cell proliferation in control and conditional mutant hearts was similar at P7, as assessed by BrdUrd incorporation (57.7 ± 2.4 BrdUrd-positive nuclei per field in conditional mutant and 61.0 ± 1.4 in control hearts).

Figure 4
Ventricular dilatation and myofiber hypertrophy in conditional ErbB2 mutant mice. Histological (AD) and electron microscopical analysis (E and F) of control (A, C, and E) and conditional ErbB2 mutant mice (B, D, and F). (A and B) Hematoxylin/eosin-stained ...

Effect of the ErbB2 Mutation on Gene Expression in the Hearts of Conditional Mutant Mice.

To identify target genes of ErbB2 signaling in the heart, RNA was isolated from the heart ventricles of control and conditional mutant mice and analyzed by Affymetrix microarray hybridization (Table (Table1).1). To minimize effects on gene expression caused by secondary changes, conditional mutant animals were analyzed at a stage when they display no overt signs of heart dysfunction: they were 12 days old and had normal weight and heart morphology. Principally, the differences observed in gene expression between control and conditional mutant hearts were small. Genes whose expression was increased included those encoding natriuretic peptides (atrial natriuretic factor; brain natriuretic peptide) and skeletal α-actin, which are typically up-regulated in compensatory cardiac hypertrophy (Table (Table1;1; see ref. 23). We identified few additional genes whose expression was changed, such as ATF3. ATF3 expression was previously reported to be up-regulated in an ischemic heart model (24), and its overexpression causes cardiac dysfunction and hypertrophy (25). Thus, the compensatory hypertrophy program commences in the hearts of conditional ErbB2 mutant mice before obvious changes in morphology and pumping function. Little overlap exists between genes whose expression is altered in conditional ErbB2 mutant hearts and those changed after addition of Neuregulins-1 and -2 to cultured epithelial cells (26) (see Supporting Information, which is published on the PNAS web site, www.pnas.org).

Table 1
Changes in gene expressison in the heart ventricle of conditional ErbB2 mutant mice

Discussion

Using conditional mutagenesis in mice, we show here that ErbB2 is essential for the normal functioning of the postnatal heart. We used Cre-loxP-mediated recombination to introduce the ErbB2 mutation in ventricular cardiomyocytes and found that the conditional mutant mice acquire a severe dilated cardiomyopathy, which is associated with the occurrence of sudden death. Sudden death accompanies dilated cardiomyopathies in mice and humans and reflects secondary changes caused by tissue injuries and fibrosis, which impair the cardiac conduction system and cause arrhythmias (27). Our findings shed new light on the clinical observations of increased risk of cardiac problems in breast cancer patients that undergo an anti-ErbB2 antibody-based tumor therapy. Cardiomyopathy is also observed after conditional mutation of ErbB4 in cardiomyocytes (Cecilia Hertig, personal communication), indicating that ErbB2 functions as an ErbB4 coreceptor in the adult heart. In general, ErbB2/ErbB4 heteromers are higher-affinity receptors than ErbB4 homomers (28). Thus, the mutation of ErbB2 in cardiomyocytes is expected to result in decreased ErbB4 ligand binding and activation.

The reasons for the adverse effects of anti-ErbB2 antibody treatment, which can lead to heart disease, were ill understood (29). We demonstrate here that the presence of ErbB2 in cardiomyocytes is essential for adult heart function. A low incidence of cardiac dysfunction (1%) is observed in patients undergoing Trastuzumab monotherapy (30). Prior exposure to anthracyclines, which are known cardiotoxic agents, increases the incidence of cardiac side effects of a Trastuzumab monotherapy to 7%. This is alarmingly augmented to 27–29% when Trastuzumab therapy is used in combination with anthracyclines or other cytostatic agents (13, 30). Thus, Trastuzumab augments previous heart damage, and it may sensitize the cardiac system to cardiotoxic agents. Beyond the essential role in the normal heart revealed by our experiments, the ErbB2 receptor might thus function also in cardioprotective responses. Further, ErbB2 down-regulation might be facilitated in damaged hearts (see also below).

Trastuzumab binds ErbB2 and induces dimerization and down-regulation of the receptor (12). Dimerization of ErbB2 in the membrane is a first step necessary for down-regulation, and low receptor concentrations are expected to reduce the efficiency of Trastuzumab's action. Thus, antibody-mediated down-regulation of ErbB2 in tissues that express low receptor levels was expected to be marginal. ErbB receptors are clustered in discrete membrane compartments through interaction with PDZ-domain-containing proteins, such as Erbin, PSD-95, or PICK1 (3133). We find that the ErbB2 and ErbB4 receptors in the heart are also localized to a specific membrane compartment, the T-tubule system. Despite the overall low abundance of ErbB2 in the heart, its increased local concentration might facilitate Trastuzumab's action. T-tubules, invaginations of the surface membrane with an average diameter of 250 nm, form a reticulum in striated muscle cells, which is open to the extracellular space and can be accessed by macromolecules (34). Dilation of T-tubules, a recognized secondary change in cardiomyopathies, might facilitate access of antibodies to T-tubules in a diseased heart (35, 36). Interestingly, such T-tubular changes were also observed after anthracycline treatment (37). However, the incidence of cardiac side effects observed in patients undergoing Trastuzumab therapy is low, and the effects are thus subtle compared with the severe cardiomyopathy observed in the conditional ErbB2 mutant mice. Thus, in hearts of patients, only a fraction of the ErbB2 receptor pool appears to be targeted and down-regulated by the antibody.

Functions of ErbB2 in Postnatal Cardiomyocytes.

Conditional ErbB2 mutant mice display a complex cardiac phenotype, which includes hypertrophy, ventricular dilatation, and decreased pumping function. Hypertrophy in healthy individuals is the consequence of prolonged biomechanical challenge of the heart (for example, exercise) and accompanies an increased cardiac pumping function (38). Hypertrophy is also frequently observed in cardiomyopathy patients but is then combined with decreased pumping function that can lead to cardiac failure, similar to what is seen in the conditional ErbB2 mutants. Generally, hypertrophy is an indicator for cardiac stress, whether induced by exercise or by pathological alterations. The hypertrophy observed in the conditional ErbB2 mutant mice can thus be interpreted as a consequence of stress caused by an underlying functional deficit in the heart.

The conditional ErbB2 mutant mice also display a lengthened time to repolarize the ventricle (increased QTc) and an absence of tachycardia, which are not usually associated with dilated cardiomyopathy in humans. Changes in K+- or Na+-channel activity in humans and mice cause increased QTc and torsades de pointes arrhythmias (39). The various symptoms in the conditional mutant mice indicate that ErbB2 takes over complex roles in the adult heart—for instance, the modulation of contractile function. ErbB receptors classically activate various signaling cascades and affect the activity of K+ channels, nonselective cation channels (TRPs), and G-protein-coupled receptors, all of which can impinge on heart function (4042). Epidermal growth factor was reported to cause acute effects on ventricular contractility and heart rate in perfused rat hearts and on K+ currents in isolated sinus node myocytes (43, 44). ErbB receptors could interact directly with proteins of the excitation–contraction coupling machinery that also locate to T-tubules. However, an acute effect of Neuregulin-1 on the frequency of spontaneous Ca2+ transients in cultured neonatal or embryonic cardiomyocytes was not seen (A.N.G., unpublished observations). It is interesting to note that in cultured human and rat cardiomyocytes, prolonged treatment with anti-ErbB2 antibody causes atrophy and a loss of contractile function, which can be overcome by long-term exposure to Neuregulins (Jay Schneider and Cary Lai, personal communication).

Loss of cardiomyocytes can also induce cardiac stress and can result in impaired pumping and hypertrophy (19, 45). Neuregulin/ErbB signaling increases survival of cultured postnatal cardiomyocytes (46), and Neuregulin-1 in combination with insulin-like growth factor I can enhance cardiomyocyte proliferation during development (47). In the hearts of the adult conditional ErbB2 mutants, we did not detect significantly increased apoptosis or changes in proliferation of cardiomyocytes. Aortic banding has revealed in other models effects on the survival of cardiomyocytes (19) but did not change apoptosis rates in conditional ErbB2 mutant mice. Furthermore, a preferential loss of homozygous ErbB2 mutant cardiomyocytes was not observed. It was possible to assess such a loss because recombination induced by Cre was not complete, resulting in a mosaicism of homozygous and heterozygous mutant cardiomyocytes in conditional mutants. The two cell types are present in similar proportions in newborn and adult hearts. Thus, mechanisms distinct from apoptosis appear to cause cardiomyopathy in conditional ErbB2 mutants, such as impaired contractility.

Gene Expression in the Heart of Conditional ErbB2 Mutant Mice.

We found that expression of natriuretic peptides [atrial natriuretic factor (ANF), brain natriuretic peptide (BNP)] and skeletal α-actin is increased in the hearts of the conditional ErbB2 mutants. Up-regulation in the expression of ANF, BNP, and actin has been previously noted in various models of cardiac hypertrophy or cardiac dysfunction (23, 48). These genes are also expressed at high levels in the developing heart, and their up-regulation in pathology was suggested to reflect a return to the embryonic gene expression program (23). The expression of genes encoding cyclin G, desmoplakin 1, insulin-like growth factor II, protein phosphatase 1cγ (PP1cγ), and pro-collagen 1 were reported as changed in hypertrophy previously (23, 48) but were not altered in our model (see Supporting Information on the PNAS web site). Some of the observed differences might reflect the distinct etiologies of the hypertrophy in the respective models. Eventually, expression profiling may allow the correlation of genetic and/or environmental causes of cardiomyopathies with alterations in gene expression. The activation of the hypertrophy program in conditional ErbB2 mutants most likely reflects a secondary response that is induced by cardiac stress resulting from impaired ErbB2 signaling.

Supplementary Material

Supporting Information:

Acknowledgments

We thank S. Schmidt, A. Leschke, T. Schalow, K. Gottschling, S. Buchert, and C. Rudolph for expert technical assistance. We are indebted to H. Schulz and J. Monti (MDC, Berlin) for assistance with the analysis of Affymetrix genechip data and Taqman real-time PCR data. We also thank C. Lindschau (FVK, Berlin) for advice and supervision on Fura-2 imaging of cardiomyocytes, G. Wallukat and M. Wegener (MDC, Berlin) for providing cultures of rat cardiomyocytes, as well as R. Dietz (FVK, Berlin) and W. Birchmeier (MDC, Berlin) for critical reading of the manuscript. This work was funded by a grant from the Volkswagen Foundation (to C.B.) and a clinical cooperation grant from the M.D.C. (to C.B. and C.Ö.).

References

1. Seidman J G, Seidman C. Cell. 2001;104:557–567. [PubMed]
2. Towbin J A. Curr Opin Cell Biol. 1998;10:131–139. [PubMed]
3. Emanueli C, Maestri R, Corradi D, Marchione R, Minasi A, Tozzi M G, Salis M B, Straino S, Capogrossi M C, Olivetti G, Madeddu P. Circulation. 1999;100:2359–2365. [PubMed]
4. Nebigil C G, Hickel P, Messaddeq N, Vonesch J L, Douchet M P, Monassier L, Gyorgy K, Matz R, Andriantsitohaina R, Manivet P, et al. Circulation. 2001;103:2973–2979. [PubMed]
5. Kiriazis H, Kranias E G. Annu Rev Physiol. 2000;62:321–351. [PubMed]
6. Yarden Y, Sliwkowski M X. Nat Rev Mol Cell Biol. 2001;2:127–137. [PubMed]
7. Bange J, Zwick E, Ullrich A. Nat Med. 2001;7:548–552. [PubMed]
8. Lemke G. Mol Cell Neurosci. 1996;7:247–262. [PubMed]
9. Garratt A N, Britsch S, Birchmeier C. BioEssays. 2000;22:987–996. [PubMed]
10. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Oncogene. 2001;20:1594–1600. [PubMed]
11. Meyer D, Birchmeier C. Nature (London) 1995;378:386–390. [PubMed]
12. Sliwkowski M X, Lofgren J A, Lewis G D, Hotaling T E, Fendly B M, Fox J A. Semin Oncol. 1999;26:60–70. [PubMed]
13. Slamon D J, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. N Engl J Med. 2001;344:783–792. [PubMed]
14. Chen J, Kubalak S W, Minamisawa S, Price R L, Becker K D, Hickey R, Ross J, Jr, Chien K R. J Biol Chem. 1998;273:1252–1256. [PubMed]
15. Minamisawa S, Gu Y, Ross J, Jr, Chien K R, Chen J. J Biol Chem. 1999;274:10066–10070. [PubMed]
16. Garratt A N, Voiculescu O, Topilko P, Charnay P, Birchmeier C. J Cell Biol. 2000;148:1035–1046. [PMC free article] [PubMed]
17. Britsch S, Li L, Kirchhoff S, Theuring F, Brinkmann V, Birchmeier C, Riethmacher D. Genes Dev. 1998;12:1825–1836. [PMC free article] [PubMed]
18. Lobe C G, Koop K E, Kreppner W, Lomeli H, Gertsenstein M, Nagy A. Dev Biol. 1999;208:281–292. [PubMed]
19. Hirota H, Chen J, Betz U A, Rajewsky K, Gu Y, Ross J, Jr, Muller W, Chien K R. Cell. 1999;97:189–198. [PubMed]
20. Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie T M, Chen J, Chien K R, Offermanns S. Nat Med. 2001;7:1236–1240. [PubMed]
21. Rohrbach S, Yan X, Weinberg E O, Hasan F, Bartunek J, Marchionni M A, Lorell B H. Circulation. 1999;100:407–412. [PubMed]
22. Kostin S, Scholz D, Shimada T, Maeno Y, Mollnau H, Hein S, Schaper J. Cell Tissue Res. 1998;294:449–460. [PubMed]
23. Friddle C J, Koga T, Rubin E M, Bristow J. Proc Natl Acad Sci USA. 2000;97:6745–6750. [PMC free article] [PubMed]
24. Chen B P, Wolfgang C D, Hai T. Mol Cell Biol. 1996;16:1157–1168. [PMC free article] [PubMed]
25. Okamoto Y, Chaves A, Chen J, Kelley R, Jones K, Weed H G, Gardner K L, Gangi L, Yamaguchi M, Klomkleaw W, et al. Am J Pathol. 2001;159:639–650. [PMC free article] [PubMed]
26. Sweeney C, Fambrough D, Huard C, Diamonti A J, Lander E S, Cantley L C, Carraway K L., 3rd J Biol Chem. 2001;276:22685–22698. [PubMed]
27. Brandenburg R O. J Am Coll Cardiol. 1985;5:185B–189B. [PubMed]
28. Jones J T, Akita R W, Sliwkowski M X. FEBS Lett. 1999;447:227–231. [PubMed]
29. Ewer M S, Gibbs H R, Swafford J, Benjamin R S. Semin Oncol. 1999;26:96–101. [PubMed]
30. Sparano J A. Semin Oncol. 2001;28:20–27. [PubMed]
31. Borg J P, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H, Fournier E, Adelaide J, Margolis B, Birnbaum D. Nat Cell Biol. 2000;2:407–414. [PubMed]
32. Carraway K L, 3rd, Sweeney C. Curr Opin Cell Biol. 2001;13:125–130. [PubMed]
33. Jaulin-Bastard F, Saito H, Le Bivic A, Ollendorff V, Marchetto S, Birnbaum D, Borg J P. J Biol Chem. 2001;276:15256–15263. [PubMed]
34. Soeller C, Cannell M B. Circ Res. 1999;84:266–275. [PubMed]
35. Carrasco Guerra H A, Palacios-Pru E, Dagert de Scorza C, Molina C, Inglessis G, Mendoza R V. Am Heart J. 1987;113:716–724. [PubMed]
36. Schaper J, Froede R, Hein S, Buck A, Hashizume H, Speiser B, Friedl A, Bleese N. Circulation. 1991;83:504–514. [PubMed]
37. Unverferth D V, Magorien R D, Unverferth B P, Talley R L, Balcerzak S P, Baba N. Cancer Treat Rep. 1981;65:1093–1097. [PubMed]
38. Hunter J J, Chien K R. N Engl J Med. 1999;341:1276–1283. [PubMed]
39. Keating M T, Sanguinetti M C. Cell. 2001;104:569–580. [PubMed]
40. Wischmeyer E, Doring F, Karschin A. J Biol Chem. 1998;273:34063–34068. [PubMed]
41. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. Nature (London) 1999;402:884–888. [PubMed]
42. Schaefer M, Plant T D, Obukhov A G, Hofmann T, Gudermann T, Schultz G. J Biol Chem. 2000;275:17517–17526. [PubMed]
43. Nair B G, Rashed H M, Patel T B. Growth Factors. 1993;8:41–48. [PubMed]
44. Wu J Y, Yu H, Cohen I S. Biochim Biophys Acta. 2000;1463:15–19. [PubMed]
45. Chien K R. Cell. 1999;98:555–558. [PubMed]
46. Zhao Y Y, Sawyer D R, Baliga R R, Opel D J, Han X, Marchionni M A, Kelly R A. J Biol Chem. 1998;273:10261–10269. [PubMed]
47. Hertig C M, Kubalak S W, Wang Y, Chien K R. J Biol Chem. 1999;274:37362–37369. [PubMed]
48. Johnatty S E, Dyck J R, Michael L H, Olson E N, Abdellatif M. J Mol Cell Cardiol. 2000;32:805–815. [PubMed]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • EST
    EST
    Published EST sequences
  • Gene
    Gene
    Gene links
  • Gene (nucleotide)
    Gene (nucleotide)
    Records in Gene identified from shared sequence links
  • GEO Profiles
    GEO Profiles
    Related GEO records
  • HomoloGene
    HomoloGene
    HomoloGene links
  • MedGen
    MedGen
    Related information in MedGen
  • Nucleotide
    Nucleotide
    Published Nucleotide sequences
  • OMIM
    OMIM
    OMIM record citing PubMed
  • Pathways + GO
    Pathways + GO
    Pathways, annotations and biological systems (BioSystems) that cite the current article.
  • PubMed
    PubMed
    PubMed citations for these articles
  • Taxonomy
    Taxonomy
    Related taxonomy entry
  • Taxonomy Tree
    Taxonomy Tree